Vancouver, Canada - Xenon Pharmaceuticals Inc., a privately held company engaged in developing novel small molecule therapies for select neurological, cardiovascular and metabolic diseases, today announced that Takeda Research Investment, Inc. (TRI) has made a strategic equity investment of USD $5M in the Company. In addition, TRI and Xenon have entered into an agreement where Takeda Pharmaceutical Company Limited, through TRI, receives a Right of First Negotiation to select atherosclerosis discoveries made by Xenon.
